Vivek Ramaswamy ramps up biotech startup #14 — this time working on a gene therapy for sickle cell disease and β-thalassemia

Vivek Ramaswamy?s Roivant Sciences has nabbed its latest clinical-stage program for biotech startup #14 ? Aruvant ? and this time they?re going up against a couple of the leaders in the gene therapy world. Their new drug is now dubbed RVT-1801, and it has a familiar profile, inserting a modified